Immunic (NASDAQ:IMUX) Research Coverage Started at Roth Capital

Roth Capital initiated coverage on shares of Immunic (NASDAQ:IMUX) in a research report sent to investors on Friday, Marketbeat.com reports. The brokerage issued a buy rating and a $3.00 price target on the stock. Roth Capital also issued estimates for Immunic’s Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.10) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.07) EPS and Q4 2026 earnings at ($0.06) EPS.

Several other equities analysts have also commented on IMUX. Chardan Capital began coverage on Immunic in a research note on Monday, September 29th. They issued a “buy” rating and a $13.00 price target on the stock. LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunic in a research note on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Immunic in a research report on Friday, September 26th. Finally, D. Boral Capital reissued a “buy” rating and issued a $10.00 target price on shares of Immunic in a research report on Thursday, September 25th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Immunic has a consensus rating of “Moderate Buy” and an average price target of $8.20.

Immunic Stock Performance

Shares of NASDAQ IMUX traded up $0.01 during midday trading on Friday, reaching $0.73. 392,019 shares of the stock were exchanged, compared to its average volume of 1,289,013. The stock has a market capitalization of $72.11 million, a P/E ratio of -0.78 and a beta of 1.53. The company has a 50 day simple moving average of $0.84 and a 200 day simple moving average of $0.87. Immunic has a twelve month low of $0.56 and a twelve month high of $1.42.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02). On average, research analysts expect that Immunic will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Immunic

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. HB Wealth Management LLC purchased a new position in shares of Immunic during the 3rd quarter worth approximately $81,000. GSA Capital Partners LLP acquired a new position in Immunic during the third quarter worth $170,000. Jane Street Group LLC raised its position in Immunic by 279.3% in the first quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock worth $226,000 after acquiring an additional 152,726 shares in the last quarter. 683 Capital Management LLC raised its position in Immunic by 28.6% in the first quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock worth $981,000 after acquiring an additional 200,000 shares in the last quarter. Finally, Aberdeen Group plc acquired a new stake in Immunic in the first quarter valued at $1,155,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.